International Psoriasis Council

subscribe
Search

Advancing Knowledge. Enhancing Care.

subscribe
Search

Advancing Knowledge. Enhancing Care.

Cyltezo®, First and Only FDA-approved Interchangeable Biosimilar to Humira®, Now Commercially Available in the United States

Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® (adalimumab), is now commercially available in the United States. Cyltezo was initially approved as a biosimilar in 2017 for use in multiple chronic inflammatory diseases. Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.

Read Full Press Release

Learn More About Cyltezo – Summary of Product Characteristics

Boehringer Ingelheim A Value Through Innovation

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Abstracts Published for the Gunnar Lomholt Symposium at IPC 2023 Think Tank

VIEW

Press Release: IPC and NPF Collaboration Reveals Impact of Psoriasis Location on Quality of Life

VIEW

Nurturing Future Leaders in Psoriasis Care: IPC International Fellowship Program Gears Up for 2024 Applications

VIEW

Also Read
Press Release

Sotyktu™ (Deucravacitinib) Recommended by the National Institute for Health and Care Excellence (NICE) for use in England as a First-in-class Treatment Option for Moderate to Severe Plaque Psoriasis in Adults

Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.

Read More
Wednesday, July 5, 2023
research

Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)

In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.

Read More
Friday, June 23, 2023

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.
Subscribe